In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...

Multiple people across the globe who stepped forward are speaking about what they say is the debilitating aftermath they now have to live with.

Public health researchers found no uptick in myositis associated with COVID-19 vaccines across Norway and Sweden in a controlled study, contradicting previous reports of the condition occurring in the ...

Roivant Sciences Ltd.'s innovative model and breakthrough autoimmune drug pipeline make it a strong buy. Click here to read an analysis of ROIV stock now.

By now, you know that the COVID-19 vaccine is the best way to protect against severe COVID infections and reduce your chances ...

A new mRNA-based flu vaccine from Pfizer has shown greater effectiveness than the standard flu shot in a large Phase 3 trial, according to results published in the New England Journal of Medicine. The ...

More than a third of Americans who were vaccinated against COVID-19 say they had side effects from the shot, and nearly half ...

Some 10% of adults who got the shot said that they were whacked by “major side effects,” and another 26% cited minor side effects.

Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side ...